N-(5-Benzyl-3-carbamoylthiophen-2-YL)-2H-13-benzodioxole-5-carboxamide

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并间二氧杂环戊烯类
• 英文名称: N-(5-Benzyl-3-carbamoylthiophen-2-YL)-2H-13-benzodioxole-5-carboxamide
• 英文别名: N-(5-benzyl-3-carbamoylthiophen-2-yl)-1,3-benzodioxole-5-carboxamide
• 化学式: C₂₀H₁₆N₂O₄S
• mdl: MFCD06005080
• 分子量: 380.4
• InChiKey: XWBVQPQOOYFADW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  27
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  119
• 氢给体数：
  2
• 氢受体数：
  5

文献信息

• NOVEL INHIBITORS OF INSULIN-LIKE GROWTH FACTOR 2 MRNA BINDING PROTEINS
  申请人：Martin-Luther-Universität Halle-Wittenberg

  公开号：EP4008716A1

  公开（公告）日：2022-06-08

  The presented invention provides compounds of formula (I), or a pharmaceutically acceptable salt, solvate or polymorph thereof, including all tautomers and stereoisomers thereof, wherein W, X, Y, Z, m, n and o are as defined herein. Said compounds of formula (I) are inhibitors of insulin-like growth factor 2 mRNA binding proteins (IGF2BP). Provided are novel inhibitors of IGF2BPs and processes for manufacturing the same. Efficacy of the new compounds is shown in solid cancer models.

  本发明提供了式 (I) 的化合物、 或其药学上可接受的盐、溶液或多晶型物，包括其所有同系物和立体异构体，其中 W、X、Y、Z、m、n 和 o 如本文所定义。所述式（I）化合物是胰岛素样生长因子 2 mRNA 结合蛋白（IGF2BP）的抑制剂。本文提供了新型 IGF2BPs 抑制剂及其生产工艺。在实体癌模型中显示了新化合物的功效。
• THIOPHENE DERIVATIVES ACTIVE AS KINASE INHIBITORS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM
  申请人：Pharmacia Italia S.p.A.

  公开号：EP1294707A2

  公开（公告）日：2003-03-26
• US6414013B1
  申请人：——

  公开号：US6414013B1

  公开（公告）日：2002-07-02
• [EN] THIOPHENE DERIVATIVES ACTIVE AS KINASE INHIBITORS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM<br/>[FR] DERIVES DE THIOPHENE ACTIFS EN TANT QU'INHIBITEURS DE KINASE, LEUR PROCEDE DE PREPARATION, ET COMPOSITIONS PHARMACEUTIQUES LES CONTENANT
  申请人：PHARMACIA & UPJOHN SPA

  公开号：WO2001098290A2

  公开（公告）日：2001-12-27

  Compounds which are 3-aminocarbonyl-2-carboxamido-thiophene derivatives or pharmaceutically acceptable salts thereof, together with pharmaceutical compositions comprising them are disclosed; these compounds or compositions are useful in the treatment of diseases caused by and/or associated with an altered protein kinase activity such as cancer, cell proliferative disorders, Alzheimer's disease, viral infections, auto-immune diseases and neurodegenerative disorders.